Skip to main content

CSL Limited

corporate_fare Company Profile

CSL Limited

CSLLY·OTC·Life Sciences·CIK 0001274152

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical products and vaccines. The company operates through three segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment focuses on manufacturing, marketing, and distributing plasma products, gene therapies, and recombinants. The CSL Seqirus segment is responsible for manufacturing, marketing, and distributing influenza-related products and providing pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products primarily in the therapeutic areas of iron deficiency and nephrology. CSL Limited's therapeutic areas include Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. The company also licenses its intellectual property and develops vaccines for the prevention of infectious diseases. CSL Limited has a strategic collaboration with Dutch biotech company VarmX BV to develop VMX-C001, which aims to help restore blood coagulation in patients requiring urgent surgery. The company distributes its products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. CSL Limited was founded in 1916 as Commonwealth Serum Laboratories Limited, changing its name to CSL Limited in October 1991, and is headquartered in Melbourne, Australia.

CSL Limited (OTC:CSLLY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for CSLLY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-04, rated 8/10.

Recent high-impact activity:

  • CSL Pays $355M Upfront for Alentis Kidney/Liver Drug in $1.6B Deal

Short Interest & Short Volume

2.07 days to cover

FINRA reported short interest of 160,435 shares in CSLLY as of the October 30, 2026 settlement, a 12.2% decrease from the prior period — about 2.1 days to cover at its recent average daily volume. On November 20, 2026, 22.4% of CSLLY volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)160,435 shares as of October 30, 2026
Change vs prior period▼ 12.2%
Days to cover2.07 at avg daily volume of 77,389
Daily short volume (FINRA facilities)22.4% of 52,073 shares on November 20, 2026
5-day average short volume17.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$32.39
52-week range · as of 2026-10-04 $16.01 – $36.28
Market cap
$63.84B
Volume
52.2K (0.4× avg)
3-mo avg 134.1K
Live data · 2026-11-21 07:14 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CSLLY - Latest Insights

CSLLY
Oct 04, 2026, 6:41 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $30.54
Real-time Price: $32.39 info
Change: +$1.85 (+6%) info
Market Cap: $63.843B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets